# Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling

> **NCT03760952** · — · COMPLETED · sponsor: **Immatics US, Inc.** · enrollment: 242 (actual)

## Conditions studied

- Refractory Cancer
- Recurrent Cancer
- Adult Solid Tumor
- Neoplasms

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03760952
- **Lead sponsor:** Immatics US, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-26
- **Primary completion:** 2022-11-15
- **Final completion:** 2022-11-15
- **Target enrollment:** 242 (ACTUAL)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03760952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03760952, "Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03760952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*